Baseline characteristics of biologic-naïve, TNFi rituximab, tocilizumab or abatacept ever-exposed RA patients
| Biologic-naïve | TNFi | Rituximab | Tocilizumab | Abatacept | |
|---|---|---|---|---|---|
| Patients (n) | 68 411 | 48 304 | 9431 | 2606 | 1563 |
| Follow-up time (pyrs) | 300 012 | 242 814 | 28 705 | 4053 | 4399 |
| Female (%) (range) | 72.1 (71–79) | 75 (74.2–87) | 78.4 (76.1–80.5) | 78.8 (77–80.2) | 78.4 (77–79.2) |
| Mean age (range) | 61.1 (57–61.8) | 55.0 (50.3–56.5) | 58 (57.5–58.6) | 56.5 (56–56.8) | 57.4 (56–58.2) |
| Mean of median disease duration (range) | 5.7 (4–13) | 8.5 (6.2–12) | 12.8 (8.6–17) | 10.3 (6–13.5) | 13.3 (8–16) |
| Mean DAS28 (range) | 4.0 (3.6–5.1) | 5.3 (3.8–6.6) | 5.4 (4.3–5.7) | 5.2 (5.1–5.3) | 5.3 (5.3–5.4) |
| Mean HAQ (range) | 1.0 (0.8–1.5) | 1.4 (0.8–2) | 1.5 (1.2–1.6) | 1.4 | 1.5 |
DAS28, disease activity score based on 28 joint counts; HAQ, Health Assessment Questionnaire; Pyrs, person-years; TNFi, tumour necrosis factor inhibitors.